34.74
price up icon0.12%   0.04
after-market Dopo l'orario di chiusura: 34.74
loading
Precedente Chiudi:
$34.70
Aprire:
$39.37
Volume 24 ore:
937.64K
Relative Volume:
2.39
Capitalizzazione di mercato:
$1.91B
Reddito:
$597.40M
Utile/perdita netta:
$-15.51M
Rapporto P/E:
47.59
EPS:
0.73
Flusso di cassa netto:
$99.84M
1 W Prestazione:
+1.05%
1M Prestazione:
+8.49%
6M Prestazione:
+12.68%
1 anno Prestazione:
+41.91%
Intervallo 1D:
Value
$33.43
$39.37
Intervallo di 1 settimana:
Value
$33.43
$39.37
Portata 52W:
Value
$23.05
$39.37

Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile

Name
Nome
Supernus Pharmaceuticals Inc
Name
Telefono
301-838-2500
Name
Indirizzo
9715 KEY WEST AVENUE, ROCKVILLE, MD
Name
Dipendente
652
Name
Cinguettio
@Supernus_Pharma
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
SUPN's Discussions on Twitter

Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-01-03 Ripresa Jefferies Buy
2021-12-01 Ripresa Jefferies Buy
2021-04-13 Aggiornamento Jefferies Hold → Buy
2020-06-16 Aggiornamento Piper Sandler Neutral → Overweight
2020-06-15 Ripresa Jefferies Hold
2019-11-08 Downgrade Berenberg Buy → Hold
2019-11-07 Downgrade Stifel Buy → Hold
2019-11-06 Downgrade Jefferies Buy → Hold
2018-11-12 Reiterato B. Riley FBR Buy
2018-01-18 Reiterato B. Riley FBR, Inc. Buy
2017-12-28 Reiterato B. Riley FBR, Inc. Buy
2017-12-04 Aggiornamento Janney Neutral → Buy
2017-11-08 Aggiornamento Stifel Hold → Buy
2017-10-19 Iniziato FBR & Co. Buy
2017-09-19 Downgrade Stifel Buy → Hold
2017-07-17 Downgrade Piper Jaffray Overweight → Neutral
2017-07-14 Iniziato Janney Neutral
2017-06-01 Aggiornamento Piper Jaffray Neutral → Overweight
2016-07-18 Downgrade Northland Capital Outperform → Market Perform
2016-07-18 Downgrade Piper Jaffray Overweight → Neutral
2016-02-08 Aggiornamento Jefferies Hold → Buy
2015-11-05 Reiterato Northland Capital Outperform
2015-10-28 Iniziato Northland Capital Outperform
Mostra tutto

Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie

pulisher
02:28 AM

Earnings call: Supernus Pharmaceuticals reported a significant increase in total revenue - Investing.com

02:28 AM
pulisher
11:20 AM

Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year High Following Earnings Beat - MarketBeat

11:20 AM
pulisher
08:07 AM

Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highli - GuruFocus.com

08:07 AM
pulisher
08:00 AM

Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance

08:00 AM
pulisher
02:28 AM

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates - MSN

02:28 AM
pulisher
Nov 04, 2024

Supernus Pharmaceuticals Reports Strong Q3 2024 Results - TipRanks

Nov 04, 2024
pulisher
Nov 04, 2024

Supernus Pharmaceuticals Q3 2024 Earnings: EPS of $0.69 Beats Es - GuruFocus.com

Nov 04, 2024
pulisher
Nov 04, 2024

Supernus Announces Third Quarter 2024 Financial Results - GlobeNewswire

Nov 04, 2024
pulisher
Nov 04, 2024

Supernus Pharmaceuticals (NASDAQ:SUPN) Issues Earnings Results - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance

Nov 04, 2024
pulisher
Nov 04, 2024

Supernus Pharmaceuticals (FRA:S49) PE Ratio : 387.50 (As of Nov. 04, 2024) - GuruFocus.com

Nov 04, 2024
pulisher
Nov 04, 2024

Supernus: Q3 Earnings Snapshot - The Washington Post

Nov 04, 2024
pulisher
Nov 04, 2024

Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 04, 2024
pulisher
Nov 04, 2024

(SUPN) On The My Stocks Page - Stock Traders Daily

Nov 04, 2024
pulisher
Nov 01, 2024

Macquarie Group Ltd Adjusts Stake in Supernus Pharmaceuticals Inc - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

Stephens Investment Management Group LLC Buys 33,710 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Dimensional Fund Advisors LP Expands Stake in Supernus Pharmaceu - GuruFocus.com

Nov 01, 2024
pulisher
Oct 31, 2024

Supernus Presents Promising Data from Open-Label Phase 2a - GlobeNewswire

Oct 31, 2024
pulisher
Oct 31, 2024

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

Supernus Pharmaceuticals reports rapid depression treatment response By Investing.com - Investing.com Australia

Oct 31, 2024
pulisher
Oct 31, 2024

Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk - Simply Wall St

Oct 31, 2024
pulisher
Oct 30, 2024

Supernus Pharmaceuticals reports rapid depression treatment response - Investing.com India

Oct 30, 2024
pulisher
Oct 28, 2024

Supernus Pharmaceuticals (SUPN) Scheduled to Post Quarterly Earnings on Monday - MarketBeat

Oct 28, 2024
pulisher
Oct 22, 2024

Attention Deficit Hyperactivity Disorder Market Projected - openPR

Oct 22, 2024
pulisher
Oct 21, 2024

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results - The Manila Times

Oct 21, 2024
pulisher
Oct 21, 2024

Supernus Pharmaceuticals to Host Conference Call and - GlobeNewswire

Oct 21, 2024
pulisher
Oct 21, 2024

Supernus Pharmaceuticals (NASDAQ:SUPN) Reaches New 12-Month HighTime to Buy? - MarketBeat

Oct 21, 2024
pulisher
Oct 19, 2024

Exchange Traded Concepts LLC Makes New Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat

Oct 19, 2024
pulisher
Oct 19, 2024

Supernus’ depression drug improved symptoms in two hours in Phase IIa study - Clinical Trials Arena

Oct 19, 2024
pulisher
Oct 18, 2024

Supernus stock holds Buy rating on MDD trial data By Investing.com - Investing.com UK

Oct 18, 2024
pulisher
Oct 18, 2024

Supernus Announces Promising Data from Open-Label Phase 2a - GlobeNewswire

Oct 18, 2024
pulisher
Oct 17, 2024

Supernus reports Phase 2a data for SPN-820, stock climbs 6% - MSN

Oct 17, 2024
pulisher
Oct 17, 2024

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with - The Bakersfield Californian

Oct 17, 2024
pulisher
Oct 17, 2024

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder - StockTitan

Oct 17, 2024
pulisher
Oct 16, 2024

SUPN (Supernus Pharmaceuticals) 3-Year EPS without NRI Grow - GuruFocus.com

Oct 16, 2024
pulisher
Oct 14, 2024

(SUPN) Trading Signals - Stock Traders Daily

Oct 14, 2024
pulisher
Oct 13, 2024

Millennium Management LLC Buys 128,743 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat

Oct 13, 2024
pulisher
Oct 10, 2024

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder - The Manila Times

Oct 10, 2024
pulisher
Oct 10, 2024

Supernus Pharmaceuticals to Host Webcast to Review - GlobeNewswire

Oct 10, 2024
pulisher
Oct 09, 2024

Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada

Oct 09, 2024
pulisher
Oct 08, 2024

Healthcare of Ontario Pension Plan Trust Fund Buys Shares of 40,000 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat

Oct 08, 2024
pulisher
Oct 05, 2024

Marshall Wace LLP Acquires Shares of 73,519 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat

Oct 05, 2024
pulisher
Oct 03, 2024

(SUPN) Technical Data - Stock Traders Daily

Oct 03, 2024
pulisher
Oct 03, 2024

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Bank of Montreal Can - MarketBeat

Oct 03, 2024
pulisher
Sep 27, 2024

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Purchased by Dimensional Fund Advisors LP - MarketBeat

Sep 27, 2024
pulisher
Sep 26, 2024

Armistice Capital LLC Has $141.03 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat

Sep 26, 2024
pulisher
Sep 25, 2024

Pulling back 3.6% this week, Supernus Pharmaceuticals' NASDAQ:SUPN) five-year decline in earnings may be coming into investors focus - Simply Wall St

Sep 25, 2024
pulisher
Sep 24, 2024

Busy Philipps Encourages Women to Take Charge of Their ADHD - GlobeNewswire

Sep 24, 2024

Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Supernus Pharmaceuticals Inc Azioni (SUPN) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
GEMAYEL GEORGES
Director
Sep 13 '24
Sale
31.33
13,886
435,048
13,315
$12.67
price up icon 0.88%
$114.96
price down icon 0.42%
$89.24
price up icon 3.56%
$58.48
price down icon 0.36%
$121.53
price up icon 0.83%
$11.61
price up icon 1.40%
Capitalizzazione:     |  Volume (24 ore):